Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who completed participation in primary phase of this study.~* Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study.~* Written informed consent obtained from the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential or be post-menopausal; if of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.~Exclusion Criteria:~* Administration of any licensed vaccines within 4 weeks prior to enrolment in this study.~* Planned administration of a vaccine not foreseen by the study protocol: 4 weeks prior to any visit or within 30 days after vaccination.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first visit or planned use during the study~* Any confirmed or suspected immunosuppressive or immunodeficient condition, or autoimmune diseases such as Guillain Barre Syndrome, based on medical history and physical examination (no laboratory testing required).~* History of hypersensitivity to vaccines.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of chronic alcohol consumption and/or drug abuse.~* Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first visit or planned use during the study.~* Pregnant or lactating women.~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first visit, or planned use during the study period.~* Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Study Arms:
- GSK1562902A M6 Group (Type: EXPERIMENTAL): Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
- GSK1562902A M12 Group (Type: EXPERIMENTAL): Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
- GSK1562902A M36 Group (Type: EXPERIMENTAL): Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).